Literature DB >> 17529859

Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.

Allison F Messina1, Kathy Katz-Gaynor, Theresa Barton, Naveed Ahmad, Faryal Ghaffar, David Rasko, George H McCracken.   

Abstract

BACKGROUND: Because the heptavalent pneumococcal conjugate vaccine has reduced vaccine-type invasive pneumococcal disease (IPD) in children, a greater proportion of IPD is now caused by nonvaccine (NVT) serotypes. We analyzed the serotypes, antimicrobial resistance profiles and genetic relatedness of Streptococcus pneumoniae responsible for IPD at Children's Medical Center of Dallas.
METHODS: S. pneumoniae isolates were collected from January 1, 1999 through December 31, 2005. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped, and their penicillin and cefotaxime susceptibility determined. The 19A isolates were further characterized by pulsed-field gel electrophoresis, multilocus sequence typing and determination of penicillin-binding proteins and mef and erm genes.
RESULTS: The incidence of IPD decreased from 93.6 cases/100,000 patients in 1999 to a nadir of 41 cases/100,000 patients in 2003 (P < 0.001). The number of IPD cases caused by serotype 19A increased, accounting for 40% of the cases of IPD in 2005. Penicillin and cefotaxime susceptibility of IPD isolates did not change from 1999 through 2005 (P = 0.687). There was a decrease in penicillin (P < 0.001) and cefotaxime (P = 0.034) susceptibility in NVT serotypes from 1999 to 2005. Molecular characterization of 19A isolates revealed a predominance of ST-199 (62%). Several highly penicillin-resistant and intermediately cefotaxime-resistant strains emerged in 2004 and 2005.
CONCLUSIONS: In Dallas, heptavalent pneumococcal conjugate vaccine reduced the incidence of IPD from 1999 to 2005 by reducing the incidence of vaccine-type disease. NVT serotypes, particularly 19A, were prevalent and more resistant to antimicrobials in 2004 and 2005.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17529859     DOI: 10.1097/INF.0b013e31805cdbeb

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  43 in total

1.  Pneumococcal vaccination: time to move on?

Authors:  Marijke Johanna Proesmans
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

2.  National hospitalization trends for pediatric pneumonia and associated complications.

Authors:  Grace E Lee; Scott A Lorch; Seth Sheffler-Collins; Matthew P Kronman; Samir S Shah
Journal:  Pediatrics       Date:  2010-07-19       Impact factor: 7.124

Review 3.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

4.  Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar.

Authors:  J Picazo; J Ruiz-Contreras; J Casado-Flores; E Giangaspro; F Del Castillo; T Hernández-Sampelayo; E Otheo; F Balboa; E Ríos; C Méndez
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 5.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.

Authors:  Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

7.  Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.

Authors:  Hyunju Lee; Moon H Nahm; Robert Burton; Kyung-Hyo Kim
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

8.  Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates.

Authors:  Azadeh Tasslimi; Erica J Sison; Elizabeth Story; David Alland; Michele Burday; Susan Morrison; Sandhya Nalmas; Stephen Smith; Pauline A Thomas; Peter Wenger; Anushua Sinha
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

9.  Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.

Authors:  Lotta Siira; Merja Rantala; Jari Jalava; Antti J Hakanen; Pentti Huovinen; Tarja Kaijalainen; Outi Lyytikäinen; Anni Virolainen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

10.  Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine.

Authors:  Alison S Laufer; Jonathan C Thomas; Marisol Figueira; Janneane F Gent; Stephen I Pelton; Melinda M Pettigrew
Journal:  Vaccine       Date:  2010-01-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.